SEC Form 4 · accession 0001209191-18-022178
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graeme Bell
Officer — EVP, Chief Financial Officer
Period of report
Mar 28, 2018
Accepted (ET)
Mar 30, 2018 · 10:20 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2018 | M | 8,000 | $13.48 | A | 21,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $13.48 | Mar 28, 2018 | M | 8,000 | D | — | Jan 2, 2027 | Common Stock | 8,000 | 202,000 | D |
Explanation of responses
- F1On January 3, 2017, the Reporting Person was granted an option to purchase 210,000 common shares under the company's 2015 Amended and Restated Stock Option and Incentive Plan. The shares reported as being purchased in this Form 4 were fully vested and exercisable as of the transaction date.